8 Results for "

Prodrug development

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "Prodrug development" in MCE Product Catalog:

8
8 Cited Publications
Cat. No.: HY-14532
CAS No.: 444805-28-1
Purity:  99.46%
Synonyms: CMX001; HDP-CDV
Target:  

CMV HSV Orthopoxvirus

Research Areas:  

Infection

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-156373
MN714 is a prodrug of MN551 (HY-156395) with enhanced cell permeability. MN714 specifically and covalently binds to SOCS2 within living cells, with an EC50 of 3.77 μM at 2 h and 2.52 μM at 8 h. MN714 serves as a chemical probe for investigating the biological mechanisms of the SOCS2 and CRL5 complex, and also functions as an E3 ligase linker for PROTAC development .
loading...
    loading...
Cat. No.: HY-W014989
CAS No.: 20408-97-3
Thioglucose is a thiosugar with antioxidant properties. Thioglucose acts as an H2S/polysulfide donor to elevate intracellular sulfane sulfur levels and promote hydropersulfide formation. Thioglucose reduces the endocytosis of gold nanoparticles by phagocytes, enhances cytotoxicity and improves biocompatibility by increasing their adsorption on the surface of cancer cells. Thioglucose can be engineered into a stimulus-responsive prodrug or functional reagent for the development of targeted nanocarriers, and is used in studies related to human breast adenocarcinoma and cervical cancer .
loading...
    loading...
Cat. No.: HY-14532S
CAS No.: 1917374-64-1
Synonyms: CMX001-d6; HDP-CDV-d6
Brincidofovir-d6 (CMX001-d6) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .
loading...
    loading...
Cat. No.: HY-W267524
CAS No.: 14464-68-7
Target:  

Drug Derivative

Research Areas:  

Cancer

H-Phe (3-CF3)-OH is a phenylalanine derivative targeting the L-type amino acid transporter 1 (LAT1, SLC7A5) as its core target, and it belongs to LAT1 substrates. H-Phe (3-CF3)-OH can be used for prodrug scaffold development and research related to multiple solid tumors .
loading...
    loading...
Cat. No.: HY-179636
CAS No.: 1335138-79-8
Target:  

Drug Intermediate

Research Areas:  

Cardiovascular Disease

DS-1040 Tosylate prodrug-1 (Compound 2) is a prodrug of DS-1040 Tosylate (Compound 1) (HY-101918). DS-1040 Tosylate prodrug-1 can be used to study thromboembolic diseases .
loading...
    loading...
Cat. No.: HY-L256
100 compounds

In modern drug discovery and chemical biology research, the azide group (-N3) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality.

The MCE Azide Structural Compound Library contains 100 compounds featuring -N3 functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.

Cat. No.: HY-L924
1,488 compounds

Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy.

To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.